IBEX 35
11.075,70 -43,20 (-0,39%) Euro Stoxx 50
4.924,72 -11,25 (-0,23%) Dólar/Euro
1,0687 -0,0029 (-0,27%) Petróleo Brent
85,56 +0,55 (+0,65%) Oro
2.319,10 -11,70 (-0,50%) Bitcoin EUR
57.537,65 +106,48 (+0,19%)
Alector, Inc. (ALEC)
Después del cierre:
Alector, Inc.
131 Oyster Point Boulevard
Suite 600
South San Francisco, CA 94080
United States
415 231 5660
https://www.alector.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 244
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Arnon Rosenthal Ph.D. | Co-Founder, CEO & Director | 1,06M | N/A | 1956 |
| Dr. Saraswati Kenkare-Mitra Ph.D. | President and Head of Research & Development | 1,29M | N/A | 1968 |
| Dr. Marc Grasso M.D. | CFO, Principal Financial Officer & Principal Accounting Officer | 728,71k | N/A | 1974 |
| Dr. Gary Romano M.D., Ph.D. | Chief Medical Officer | 752,17k | N/A | 1962 |
| Mr. Peter Heutink Ph.D. | Chief Scientific Officer | N/A | N/A | N/A |
| Katie Hogan | Senior Director of Corporate Communication & Investor Relations | N/A | N/A | N/A |
| Ms. Danielle Pasqualone J.D., Ph.D. | General Counsel | N/A | N/A | N/A |
| Ms. Clare Hunt M.B.A. | Chief People Officer | N/A | N/A | N/A |
| Ms. Kristina Cutter M.P.H. | Chief Regulatory, Pharmacovigilance, & Quality Assurance Officer | N/A | N/A | N/A |
| Ms. Virginia DeJesus-Rueff M.B.A. | Chief of Staff & Head of Strategy | N/A | N/A | N/A |
Descripción
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
Gobierno corporativo
El ISS Governance QualityScore de Alector, Inc., a día 1 de junio de 2024, es 6. Las puntuaciones base son Auditoría: 6; Tablero: 3; Derechos de los accionistas: 8; Compensación: 8.
